Abstract
Background Several COVID-19 vaccine efficacy trials are ongoing with others predicted to start soon. Diagnostic work-up of trial participants following any COVID-19 associated symptom will lead to extensive testing, potentially overwhelming laboratory capacity whilst primarily yielding negative results. We aimed to identify an efficient symptom combination to capture most cases using the lowest possible number of tests.
Methods UK and US users of the COVID-19 Symptom Study app who reported new-onset symptoms between March-September 2020 and an RT-PCR test within seven days of symptom onset were included. Sensitivity, specificity, and number of RT-PCR tests needed to identify one RT-PCR positive case were calculated for individual symptoms and symptom combinations. A multi-objective evolutionary algorithm was applied to generate symptom combinations with good trade-offs between sensitivity and specificity.
Findings The UK dataset included 122,305 individuals (1,202 RT-PCR positive). Findings were replicated in a US dataset including 3,162 individuals (79 RT-PCR positive). Within three days of symptom onset, the COVID-19 specific symptom combination (cough, dyspnoea, fever, anosmia/ageusia) identified 69% of cases requiring 47 RT-PCR tests per positive case. The symptom combination with highest sensitivity was fatigue, anosmia, cough, diarrhoea, headache, and sore throat, identifying 96% of cases and requiring 96 tests.
Interpretation We confirm the significance of COVID-19 specific symptoms widely recommended for triggering RT-PCR. By using the data-driven optimization technique we identified additional symptoms (fatigue, sore throat, headache, diarrhoea) that enabled many more positive cases to be captured efficiently. By providing a set of solutions with optimal trade-offs between sensitivity and specificity, we produced a selection of symptom subsets that maximise the capture of cases given different laboratory capacities. The methodology may be of particular use for COVID-19 vaccine developers across a range of resource settings and have more far-reaching public health implications for detection of symptomatic SARS CoV2 infection.
Funding Zoe Global Limited, Department of Health, Wellcome Trust, Engineering and Physical Sciences Research Council (EPSRC), National Institute for Health Research (NIHR), Medical Research Council (MRC), Alzheimer’s Society, Massachusetts Consortium for Pathogen Readiness (MassCPR), Coalition for Epidemic Preparedness Innovations (CEPI)
Evidence before this study We searched PubMed up to November 16, 2020, with the terms “COVID-19” OR “SARS-CoV-2” AND “symptom” AND “community-based”, with no date or language restrictions, to find information about symptoms associated with COVID-19 from the community setting. The search retrieved 68 articles; however, most were not relevant as related to specific subgroups (e.g. pregnant women, cancer patients) or aspects (e.g. mental health, diagnostic testing). Fever, cough, dyspnoea, tachypnoea, anosmia, and ageusia are the symptoms most commonly identified in COVID-19 patients and typically included in guidelines from the WHO and similar bodies. These data however come primarily from hospital-based studies. An assessment of the value of symptom combinations in the community in predicting COVID-19 is lacking.
Added value of this study We present data from the largest, prospective community-based cohort study to date and quantify the contribution of various COVID-19 symptoms and symptom-combinations to RT-PCR positive COVID-19 case-finding. Our study is unique in that it simulates PCR testing in a clinical trial situation. Newly-symptomatic individuals were investigated at three days of symptom onset, and a second analysis of symptoms that occurred within seven days of symptom onset was also included to capture delayed symptom triggers. We confirm the significance of symptoms (e.g. fever, cough, anosmia/ageusia) widely used for triggering a RT-PCR test and identified additional symptoms such as fatigue, headache, sore throat, and diarrhoea to define the most efficient symptom combinations.
Implications of all the available evidence The applied methodology enables the selection of symptom subsets to maximise the capture of cases while taking account of specific laboratory capacity. Our findings have important implications for COVID-19 vaccine developers to optimise the choice of triggering symptoms for diagnostic work-up COVID-19 vaccine efficacy trials and also implications for public health due to the community-based nature of the data source used.
Competing Interest Statement
JW, RD, JCP, AM are employees of Zoe Global Ltd. ATC reports grants from Massachusetts Consortium on Pathogen Readiness, during the conduct of the study; personal fees from Pfizer Inc., grants and personal fees from Bayer Pharma; CEPI (authors AC, JG, JPC, AEL) funds clinical trials of COVID-19 vaccines. All other authors declare no competing interests.
Funding Statement
Zoe Global Limited, Department of Health, Wellcome Trust, Engineering and Physical Sciences Research Council (EPSRC), National Institute for Health Research (NIHR), Medical Research Council (MRC), Alzheimer's Society, Massachusetts Consortium for Pathogen Readiness (MassCPR), Coalition for Epidemic Preparedness Innovations (CEPI)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics has been approved by KCL Ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all participants provided consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data collected in the COVID-19 Symptom Study smartphone application are being shared with other health researchers through the UK National Health Service-funded Health Data Research UK (HDRUK) and Secure Anonymised Information Linkage consortium housed in the UK Secure Research Platform (Swansea, UK). Anonymised data are available to be shared with HDRUK researchers according to their protocols in the public interest (https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259). US investigators are encouraged to coordinate data requests through the Coronavirus Pandemic Epidemiology Consortium (https://www.monganinstitute.org/cope-consortium).
https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259
